Agomab Spain S.l.u.
Clinical trials sponsored by Agomab Spain S.l.u., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Radioactive tracer reveals how potential Crohn's drug moves through the body Results expected Sep 2026 (estimated)
-
New hope for Crohn's patients: drug may prevent bowel surgery
Disease control CompletedThis study tests an experimental drug called AGMB-129 in about 100 people with Crohn's disease who have painful bowel narrowing (strictures). The goal is to see if the drug is safe and can help reduce the narrowing, potentially avoiding the need for surgery. Participants receive …
Phase 2 • Sponsor: Agomab Spain S.L.U. • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New drug for Crohn's scarring passes early safety check in healthy volunteers
Knowledge-focused CompletedThis early-stage study tested the safety of AGMB-129, a potential drug for fibrostenotic Crohn's disease, in 30 healthy adults. Participants received multiple doses of the drug or a placebo to see how well it was tolerated and how the body processes it. The goal was to find safe …
Phase 1 • Sponsor: Agomab Spain S.L.U. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC